Figure 7
There are higher levels of active cPKC in human invasive breast cancer triple negative cells and tumors as compared to ER+.
(A) Immunolocalization of active cPKCs as detected by anti-C2Cat antibody in cells treated or non-treated with PMA (100 nM for 15 minutes), in triple negative (MDA-MB231) cells and in ER+ (MCF-7) cells. (B) Representative examples of breast tumor samples from patients with ER+ and triple negative tumors probed with anti-C2Cat. An area containing exclusively tumor cells was selected by an experienced pathologist and evaluated using digital automated quantification, where red pixels indicate strong positive staining, orange positive staining and yellow weak positive staining according to the default parameter settings strong positive <220, positive = 220-175, weak positive = 175-100 and negative = 100-0). (C) Quantitative analysis of 105 ER+ and 29 triple negative samples probed with anti-C2Cat and commercially available anti PKCα (sc-208) and γ (SC-211) antibodies (1:100), where ***p < 0.0001, unpaired t-test. Y-axis scale represents stained tissue light absorbance and is expressed as 256-Intensity average to show a higher box-plot for triple negative tumors.
